Conclusion of non-exclusive discount agreements pursuant to section 130a SGB V concerning various active substances / combinations with possible termination at any time under the so-called “open-house procedure”. The earliest start of the contract is 1.5.2017. The term of the contract is 24 months. The information is non-binding.

Substance Raltegravir § 130a Paragraph 8 SGB V (German Law, Sozialgesetzbuch V der Gesetzliche Krankenversicherung) allows health insurance companies and pharmaceutical companies to conclude framework agreements on the medicinal products to be charged to the statutory health insurance funds. The DAK health insurance fund carries out an award procedure according to the regulations of the fourth part of the GWB. The duration of the framework contract is 24 months. Deadline for tendering: 5.4.2017 The information is non-binding.

Warning: sprintf(): Too few arguments in /customers/3/3/e/ on line 146

German health care market with growth weaknesses

Categories Breaking News Health Care Feed

Germany has the second largest current account surplus in the world. A surplus of current account surplus is generated when Germany exports significantly more than imported and gives more money. In 2015, a new record surplus in the trade balance of 248 billion euros was achieved. The german medical technology sector is very export intensive. In 2015, the export rate was 65 percent. According to the USA, Germany still ranks ahead of Japan with the two-strong world trade share. 38 percent of German exports went to…Continue Reading “German health care market with growth weaknesses”